MRMaria C. Russell

Maria C. Russell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria C. Russell has a total of 226 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Decreasing Complications After Ivor‐Lewis Esophagectomy: Is a Totally Minimally Invasive Approach the Solution?

    by Parit T. Mavani, Caitlin Sok, Pranay S. Ajay, Yichun Cao, Alicia M. Bonanno, Kenneth Cardona, Felix G. Fernandez, Seth D. Force, Onkar V. Khullar, Maria C. Russell, et al.

    Background: Despite improvements over time, Ivor Lewis Esophagectomy (ILE), a potentially curative surgical option for patients with invasive esophageal cancer, carries high morbidity and mortality. We analyzed postoperative outcomes in patients undergoing ILE at our institution, comparing open (OE), hybrid (HE), and totally minimally invasive (TMIE) approaches.Methods: We reviewed the records of patients who underwent elective ILE for benign or malignant pathology at our institution (2018–2022). Patients who underwent transhiatal or McKeown esophagectomy, as well as those undergoing emergent procedures, were excluded. Factors associated with major postoperative complications (Clavien‐Dindo Grade ≥ 3) were assessed using multivariable analysis (MVA).Results: Of 260 patients, 135 met the inclusion criteria: 40 (29.6%) underwent OE, 50 (37.0%) underwent HE, and 45 (33.3%) underwent TMIE. Median length of stay was shorter for patients undergoing TMIE compared to OE and HE (9 vs. 12 and 13 days, p < 0.001). A higher major postoperative complication rate was noted in patients undergoing OE and HE compared to TMIE (32.5% and 36% vs. 13.3%) (p = 0.03). This result persisted on MVA (OE: aOR 3.4, p = 0.04; HE: aOR 5.5, p = 0.002; reference:TMIE).Conclusion: A totally minimally invasive approach to Ivor‐Lewis Esophagectomy is associated with lower major postoperative complications and shortened length of stay at our institution. Prospective evaluations in the United States population are warranted to optimize and standardize surgical approaches.

  • Prehabilitation and Immunonutrition in Pancreatic Cancer Therapy

    by Madeline Roorbach, Whitney Bleakley, Maria C. Russell

  • Comparing barriers to early stage diagnosis of hepatocellular carcinoma between safety net hospitals and academic medical centers: An analysis from the United States Safety‐Net Collaborative

    by Sophia L. Stylianos, Caroline R. Goel, Rachel M. Lee, Adam Yopp, Joshua Kronenfeld, Neha Goel, Jashodeep Datta, Ann Lee, Eric Silberfein, Maria C. Russell, et al.

    Background and Objectives: Early detection of hepatocellular carcinoma (HCC) is associated with improved survival. However, a greater proportion of patients treated at safety net hospitals (SNHs) present with late‐stage disease compared to those at academic medical centers (AMCs). This study aims to identify barriers to diagnosis of HCC, highlighting differences between SNHs and AMCs.Methods: The US Safety Net Collaborative‐HCC database was queried. Patients were stratified by facility of diagnosis (SNH or AMC). Patient demographics and HCC screening rates were examined. The primary outcome was stage at diagnosis (AJCC I/II—“early”; AJCC III/IV—“late”).Results: 1290 patients were included; 50.2% diagnosed at SNHs and 49.8% at AMCs. At SNHs, 44.4% of patients were diagnosed late, compared to 27.6% at AMCs. On multivariable regression, Black race was associated with late diagnosis in both facilities (SNH: odds ratio 1.96, p = 0.03; AMC: 2.27, p = 0.04; AMC: 0.37, p < 0.01).Conclusions: Black race was associated with late diagnosis of HCC, while screening was associated with early diagnosis across institutional types. These results suggest socially constructed racial bias in screening and diagnosis of HCC. Screening efforts targeting SNH patients and Black patients at all facilities are essential to reduce disparities.


  • Liver

    by David A. Faber, Maria C. Russell

  • Is Screening for Hepatocellular Carcinoma Effective?

    by Rachel M. Lee, Maria C. Russell


  • Early experience with robotic central pancreatectomy with patient‐reported outcomes and comparison with open central pancreatectomy

    by Pranay S. Ajay, Nina L. Eng, Caitlin P. Sok, Danielle E. Mustin, Kenneth Cardona, Juan M. Sarmiento, Mihir. M. Shah, Maria C. Russell, Shishir K. Maithel, David A. Kooby

    Background: Robotic central pancreatectomy (CP) has emerged in recent years as a noninferior approach to open CP and may offer improved patient‐reported outcomes and reduction in incisional hernias.Methods: All patients who underwent open and robotic CP between (2013 and 2022) were selected, and perioperative outcomes were analyzed. Patients who underwent robotic CP were interviewed over the phone to assess patient‐reported postoperative outcomes.Results: A total of 18 CP operations (56%—open vs. 44%—robotic) were identified. The overall median age was 67 years (interquartile range: 60–72), and 50% (n = 9) of patients were female. Median length of surgery was statistically longer for robotic CP (411 vs. 138 min, p = 0.002); all other intraoperative variables were similar. Postoperatively, a similar number of patients in the open and robotic cohorts developed clinically significant postoperative pancreatic fistulas (37.5% vs. 30%, p = 1) and major complications (37.5% vs. 20%, p = 0.60), respectively. No patients in the robotic cohort developed an incisional hernia, compared to 40% (n = 4) in open (p = 0.08). All patients returned to a baseline level of activity and reported a high quality of life.Conclusion: With the exception of longer operative times, robotic CP is a noninferior, definitive resection technique for select lesions of the middle pancreas. Additionally, the robotic approach may result in a reduction in incisional hernia development.


  • Implementation of a Hepatocellular Carcinoma Screening Program for At-risk Patients Safety-Net Hospital: A Model for National Dissemination

    by Rachel M. Md Lee, Rapheisha Darby, Caroline R. Medin, Grace C. Haser, Meredith C. Mason, Lesley S. Miller, Charles A. Staley, Shishir K. Maithel, Maria C. Russell

    Objective: This study aimed to enhance hepatocellular carcinoma (HCC) screening to achieve earlier diagnosis of patients with hepatitis C (HCV) cirrhosis in our Safety-Net population. Background: Adherence to HCC screening guidelines at Safety-Net hospitals is poor. Only 23% of patients with HCC at our health system had a screening exam within 1-year of diagnosis and 46% presented with stage IV disease. HCV-induced cirrhosis remains the most common etiology of HCC (75%) in our patients. Methods: In the setting of an established HCV treatment clinic, an HCC screening quality improvement initiative was initiated for patients with stage 3 fibrosis or cirrhosis by transient elastography. The program consisted of semiannual imaging. Navigators scheduled imaging appointments and tracked compliance. Results: From April 2018 to April 2021, 318 patients were enrolled (mean age 61 years, 81% Black race, 38% uninsured). Adherence to screening was higher than previously reported: 94%, 75%, and 74% of patients completed their first, second, and third imaging tests. Twenty-two patients (7%) were diagnosed with HCC; 55% stage I and 14% stage IV. All patients were referred and 13 (59%) received treatment. Median time to receipt of treatment was 77 days (range, 32–282). Median overall survival for treated patients was 32 months. Conclusions: Implementation of an HCC screening program at a safety-net hospital is feasible and facilitated earlier diagnosis in this study. Patient navigation and tracking completion of imaging tests were key components of the program’s success. Next steps include expanding the program to additional at-risk populations.


  • Diagnostic laparoscopy is underutilized in the staging of gastric adenocarcinoma regardless of hospital type: An US safety net collaborative analysis

    by Aleeza J. Leder Macek, Annie Wang, Michael K. Turgeon, Rachel M. Lee, Maria C. Russell, Matthew R. Porembka, Rodrigo Alterio, Michelle Ju, Joshua Kronenfeld, Neha Goel, et al.

    Background: Diagnostic laparoscopy (DL) is a key component of staging for locally advanced gastric adenocarcinoma (GA). We hypothesized that utilization of DL varied between safety net (SNH) and affiliated tertiary referral centers (TRCs).Methods: Patients diagnosed with primary GA eligible for DL were identified from the US Safety Net Collaborative database (2012–2014). Clinicopathologic factors were analyzed for association with use of DL and findings on DL. Overall survival (OS) was analyzed by Kaplan–Meier method.Results: Among 233 eligible patients, 69 (30%) received DL, of which 24 (35%) were positive for metastatic disease. Forty percent of eligible SNH patients underwent DL compared to 21.5% at TRCs. Lack of insurance was significantly associated with decreased use of DL (OR 0.48, p < 0.01), while African American (OR 6.87, p = 0.02) and Asian race (OR 3.12, p ≤ 0.01), signet ring cells on biopsy (OR 3.14, p < 0.01), and distal tumors (OR 1.62, p < 0.01) were associated with increased use. Median OS of patients with a negative DL was better than those without DL or a positive DL (not reached vs. 32 vs. 12 months, p < 0.005, Figure 1).Conclusions: Results from DL are a strong predictor of OS in GA; however, the procedure is underutilized. Patients from racial minority groups were more likely to undergo DL, which likely accounts for higher DL rates among SNH patients.


  • The aborted Whipple: Why, and what happens next?

    by Mihir M. Shah, Pranay S. Ajay, Rebecca S. Meltzer, Mohammad R. Jajja, Cricket R. Gullickson, Kenneth Cardona, Maria C. Russell, Juan M. Sarmiento, Shishir K. Maithel, David A. Kooby

    Background: For patients with periampullary adenocarcinoma (PAC), pancreatoduodenectomy (PD) provides the best survival. Surgery on a subset of patients is aborted during PD. We analyzed these patients.Methods: Patients who underwent laparotomy for planned PD for PAC were identified (2006–2019). From operative notes, we identified the subset with intraoperative decision to abort. Patient, treatment, and outcome data were analyzed. The subset with pancreatic ductal adenocarcinoma (PDAC) was analyzed for survival.Results: Only 6.7% (n = 55/819) of cases were aborted. Majority 78% (n = 43) had pathologically‐confirmed diagnoses at time of surgery, and 18.2% (n = 10) received preoperative chemotherapy. Reasons for aborted PD included: distant metastases (65.5%, n = 36) and local invasion (34.5%, n = 19). Of patients with metastatic disease, 75% (n = 27) had liver metastases. Eighty‐nine percent (n = 49) of patients underwent at least one palliative bypass procedure and 81.8% (n = 45) had both gastric and biliary bypass. Patients with computed tomography (CT) scans before surgery more commonly had missed metastatic disease (79.2% CT compared to 54.8% magnetic resonance imaging [MRI], χ2 = 3.54, p = 0.059). In PDAC, 61.4% (n = 27/44) were aborted for metastatic disease and 38.7% (n = 17/44) for local invasion. Median overall survival for all PDAC patients after aborted PD was 334 days.Conclusion: Majority of pancreatoduodenectomies for periampullary adenocarcinoma are done to completion. Liver metastases is the most common reason for aborting. Preoperative MRI may help identify hepatic metastases.


  • Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safety‐Net Collaborative analysis

    by Joshua P. Kronenfeld, Amber L. Collier, Michael K. Turgeon, Michelle Ju, Rodrigo Alterio, Annie Wang, Manuel Fernandez, Matthew R. Porembka, Harry Richter, Ann Y. Lee, et al.

    Background: Neoadjuvant chemotherapy (NAC) is standard management for localized gastric cancer (GC). Attrition during NAC due to treatment‐related toxicity or functional decline is considered a surrogate for worse biologic outcomes; however, data supporting this paradigm are lacking. We investigated factors predicting attrition and its association with overall survival (OS) in GC.Methods: Patients with nonmetastatic GC initiating NAC were identified from the US Safety‐Net Collaborative (2012–2014). Patient/treatment‐related characteristics were compared between attrition/nonattrition cohorts. Cox models determined factors associated with OS.Results: Of 116 patients initiating NAC, attrition during prescribed NAC occurred in 24%. No differences were observed in performance status, comorbidities, treatment at safety‐net hospital, or clinicopathologic factors between cohorts. Despite absence of distinguishing factors, attrition was associated with worse OS (median: 11 vs. 37 months; p = 0.01) and was an independent predictor of mortality (hazard ratio [HR]: 4.7, 95% confidence interval [CI]: 1.5–15.2; p = 0.02). Fewer patients with attrition underwent curative‐intent surgery (39% vs. 89%; p < 0.001). Even in patients undergoing surgical exploration (n = 89), NAC attrition remained an independent predictor of worse OS (HR: 50.8, 95% CI: 3.6–717.8; p = 0.004) despite similar receipt of adjuvant chemotherapy.Conclusion: Attrition during NAC for nonmetastatic GC is independently associated with worse OS, even in patients undergoing surgery. Attrition during NAC may reflect unfavorable tumor biology not captured by conventional staging metrics.